Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention

Circulation

Volumn 100, Issue 19, 1999, Pages 1977-1982

  Steinhubl, Steven R ^a   Kottke Marchant, Kandice ^c   Moliterno, David J ^b   Rosenthal, Monique L ^b   Godfrey, Nikki K ^c   Coller, Barry S ^d   Topol, Eric J ^b   Lincoff, A Michael ^b  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b Department of Cardiology   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Abciximab; Angioplasty; Diabetes mellitus; Platelets

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE ANOMALY; THROMBOCYTE FUNCTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0033539530     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.19.1977     Document Type: Article

References (26)

1. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H. Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents. Ann NY Acad Sci. 1991;614:193-213.
2. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994;90:1757-1764.
3. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
4. Classman AB. Platelet abnormalities in diabetes mellitus. Ann Clin Lab Sci. 1992;23:47-50.
5. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ, for the EPISTENT Investigators. Long-term complimentary clinical benefit of stenting and platelet glycoprotein IIb/IIIa blockade. N Engl J Med. 1999.
6. Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson K, Weisman HF, Califf RM, Topol EJ, for the EPILOG Investigators. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. Circulation. 1998;97:1912-1920.
7. Coller BS, Lang D, Scuddr LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation. 1997;95:860-867.
8. Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS. The rapid platelet function assay (RPFA): an automated and quantitative cartridge-based method. Circulation. 1999;99:620-625.
9. Smith JW, Lee T, Coleman J, Ratnikov B, Ly Y, Carette S, Fernandez D, Frelinger L, Coller BS, Hillman RS. The rapid platelet function assay: a quantitative method for point of care platelet monitoring. Blood. 1997; 90(suppl 1):3028.
10. Sharpe PC, Trinick T. Mean platelet volume in diabetes mellitus. Q J Med. 1993;86:739-742.
11. Kip KE, Faxon DP, Detre KM, Yeh WL, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1996;94:1818-1825.
12. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA, Douglas JS, Morris DC, King SB. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995;91:979-989.
13. The BARI Investigators. Comparison of coronary artery bypass surgery with angioplasty in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). N Engl J Med. 1996;335:217-225.
14. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
15. Winocour PD, Perry DW, Kinlough-Rathbone RL. Hypersensitivity to ADP of platelets from diabetic rats associated with enhanced fibrinogen binding. Eur J Clin Invest. 1992;22:19-23.
16. Oskarsson HJ, Hofmeyer TG. Platelets from patients with diabetes mellitus have impaired ability to mediate vasodilatation. J Am Coll Cardiol. 1996;27:1464-1470.
17. Bath PMW, Butterworth RJ. Platelet size measurement, physiology and vascular disease. Blood Coagul Fibrin. 1996;7:157-161.
18. Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehreh B, Osterman H, Gries FA. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest. 1990;20:166-170.
19. Cohen I, Burk D, Fullerton RJ, Veis A, Green D. Nonenzymatic glycation of human blood platelet proteins. Thromb Res. 1989;55:341-349.
20. Sampietro T, Lenzi S, Cecchetti P, Giampietro O, Cruschelli L, Navalesi R. Nonenzymatic glycation of human membrane proteins in vitro and in vivo. Clin Chem. 1986;32:1328-1331.
21. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol. 1995;26:1665-1671.
22. Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, Weisman HF, Jordan RE. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPIIb/IIIa therapy. Circulation. 1997;96:3860-3866.
23. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 1998;97:1680-1688.
24. Simoons ML, de Boer MJ, van den Brand MJBM, van Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, van der Wieken LR, De Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen KM, Stibbe J, de Feyter PJ, and the European Cooperative Study Group. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994;89:596-603.
25. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmen S, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E, for the TIMI 12 Investigators. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation. 1998;97:340-349.
26. Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, DeFranco AC, Ellis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation. 1997;96:76-81.